*Disseminated on Behalf of GT Biopharma, Inc. Please see disclosures below. |
| Keep an Eye on "GTBP" This Morning... |
| | | | | Hey Folks,
Here are a few reasons why GT Biopharma (GTBP) is worth paying attention to:
1. Big Pharma Is Paying Billions for Similar Tech — Sanofi, Gilead, and Roche have collectively spent billions acquiring or licensing NK cell technology from competitors, validating the space GT Biopharma operates in. 2. Their Lead Drug Is Already in Human Trials — GTB-3650 started dosing patients in January 2025 and has advanced through four cohorts with six patients treated and no major safety issues reported. 3. Early Clinical Data Shows the Drug Is Working — Blood tests from trial patients confirm the therapy is activating and multiplying NK cells exactly as designed. 4. Their Second-Generation Tech Is 40x More Potent — Preclinical data shows the current platform is 10-40 times stronger than the first-generation version that already showed efficacy. 5. A Safer Alternative to CAR-T — Unlike CAR-T therapies that can land patients in the ICU, GT Biopharma's approach has shown minimal side effects in trials so far. 6. Off-the-Shelf, Not Custom-Built — Their platform eliminates the weeks-long, $400,000+ manufacturing process that makes CAR-T so expensive and slow.
Anyways...
That's all for now!
Until Next Time, -ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of GT Biopharma, Inc. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. |
| This email was sent to punjabsvera@gmail.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via email, SMS, and YouTube on behalf of GT Biopharma, Inc. (GTBP) from January 14, 2026 to January 15, 2026. The reader should assume that paying parties, clients of paying parties, and third parties may own shares and may sell shares during or after this campaign, which could negatively impact the stock price. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for GT Biopharma, Inc. (GTBP). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in GT Biopharma, Inc. (GTBP). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of GT Biopharma, Inc. (GTBP), increased trading volume, and possibly an increased share price of GT Biopharma, Inc. (GTBP), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
